Malignant Ovarian Brenner Tumor

7 clinical trials · Condition

Record	Firm	Date
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors (NCT03641287)	University of Washington	2018-12-05
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02923739)	M.D. Anderson Cancer Center	2017-05-05
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT02068794)	Mayo Clinic	2014-04-25
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00719303)	Gynecologic Oncology Group	2012-06-18
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT01097746)	M.D. Anderson Cancer Center	2010-04-14
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00951496)	National Cancer Institute (NCI)	2009-08-11
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy (NCT00899093)	Gynecologic Oncology Group	2007-09-01

Every clearance here is in the API, with alerts when new ones post.